Inhibitors of the Renal Outer Medullary Potassium Channel
申请人:Pasternak Alexander
公开号:US20130217680A1
公开(公告)日:2013-08-22
This invention relates to compounds having structural Formula (I); and pharmaceutically acceptable salts thereof which are inhibitors of the Renal Outer Medullary Potassium (ROMK) channel (Kir 1.1). The compounds of Formula I are useful as diuretics and natriuretics and therefore are useful for the therapy and prophylaxis of disorders resulting from excessive salt and water retention, including cardiovascular diseases such as hypertension and chronic and acute heart failure.
[EN] HYDROXAMIC ACID COMPOUND HAVING ENPP1 INHIBITORY ACTIVITY AND USE THEREOF<br/>[FR] COMPOSÉ D'ACIDE HYDROXAMIQUE AYANT UNE ACTIVITÉ INHIBITRICE DE L'ENPP1 ET SON UTILISATION<br/>[ZH] 具有ENPP1抑制活性的异羟基肟酸类化合物及其用途
INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL
申请人:Merck Sharp & Dohme Corp.
公开号:EP2632464B1
公开(公告)日:2015-04-29
US9056859B2
申请人:——
公开号:US9056859B2
公开(公告)日:2015-06-16
[EN] INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL<br/>[FR] INHIBITEURS DU CANAL À POTASSIUM DE LA MEDULLA EXTERNE DU REIN
申请人:MERCK SHARP & DOHME
公开号:WO2012058134A1
公开(公告)日:2012-05-03
This invention relates to compounds having structural Formula (I); and pharmaceutically acceptable salts thereof which are inhibitors of the Renal Outer Medullary Potassium (ROMK) channel (Kir 1.1). The compounds of Formula I are useful as diuretics and natriuretics and therefore are useful for the therapy and prophylaxis of disorders resulting from excessive salt and water retention, including cardiovascular diseases such as hypertension and chronic and acute heart failure.